News | Radiation Therapy | April 16, 2020

Funding continues momentum of recent FDA clearance and first system order

Funding continues momentum of recent FDA clearance and first system order

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced the close of a $100 million equity financing led by Public Sector Pension Investment Board (PSP Investments), one of Canada’s largest pension investment managers that focuses on long-term investments with partners demonstrating strong value orientation strategies.

“RefleXion’s bold vision for the future of cancer care stands to completely reshape how physicians think about treating patients with stage 4 cancer,” said Loïc Julé, managing director, Global Investment Partnerships Portfolio, PSP Investments.“This is exactly the mindset of companies we strive to build long-term relationships with. We are thrilled to support RefleXion during this next phase of their growth as they ramp up market and clinical adoption of this groundbreaking technology.”

RefleXion’s existing investors, TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc., all participated in the round. BofA Securities and Morgan Stanley & Co., LLC acted as placement agents for the company.

“This new influx of capital continues our momentum initiated first by FDA clearance of the RefleXion X1 platform last month, then quickly followed by the close of our first system order at one of the world’s leading cancer centers,” said Todd Powell, president and CEO of RefleXion. “The support of this top-tier investment syndicate enables us to further scale operations around commercializing the X1 platform.

“Moreover, these funds allow us to validate the practical implications of using BgRT on a daily basis as we transform radiotherapy from early-stage cancer treatment to an option for patients with all stages of cancer,” continued Powell.

The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that currently restrict radiotherapy to one or two tumors. When available, RefleXion will scale BgRT to treat all visible tumors, even those that move rapidly due to bodily functions such as breathing or digestion, in the same treatment session.

RefleXion recently announced  FDA clearance for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), and its first clinical and commercial client.

For more information: www.reflexion.com/


Related Content

News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
News | Treatment Planning

November 26, 2023 — TeleDaaS, PLLC, a leading dosimetry-as-a-service provider, made its official debut today at the ...

Time November 26, 2023
arrow
News | Breast Imaging

November 21, 2023 —iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and CancerIQ ...

Time November 21, 2023
arrow
News | Breast Imaging

November 20, 2023 — The American Society for Radiation Oncology (ASTRO) issued a clinical guideline on partial breast ...

Time November 20, 2023
arrow
News | Artificial Intelligence

November 15, 2023 — The 2023 Radiological Society of North America (RSNA) Alexander R. Margulis Award for Scientific ...

Time November 15, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from www.itnonline.com ...

Time November 06, 2023
arrow
News | ASTRO

November 3, 2023 —The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time November 03, 2023
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Imaging advancements, including 3D Doppler imaging to detect cancers in numerous organs, are used to accurately guide ...

Time November 03, 2023
arrow
Feature | Radiation Oncology | By Christine Book

Howard Sandler, MD, FASTRO, Radiation Oncology Department Chair at Cedars-Sinai Medical Center, took the helm as ...

Time November 03, 2023
arrow
News | Artificial Intelligence

November 2, 2023 — GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with ...

Time November 02, 2023
arrow
Subscribe Now